Melatonin suppresses hyperglycemia caused by intracerebroventricular injection of 2-deoxy-D-glucose in rats.
To elucidate the role of melatonin (MT), we examined the effects of intracranial injection of MT and an MT-antagonist (S20928) on the hyperglycemic response to intracranial injection of 2-deoxy-D-glucose (2DG) in rats. The hyperglycemic and hyperglucagonemic responses caused by intracerebroventricular injection of 2DG were inhibited by intracerebroventricular co-injection of MT, but enhanced by co-injection of the MT-antagonist. Intraperitoneal injection of MT also inhibited the hyperglycemic response, though the inhibition seemed to be less than that after intracranial injection of MT. These results suggest that MT plays an endogenously suppressive role in the hyperglycemia caused by 2DG, possibly through a brain site.
Shima
T
T
Division of Protein Metabolism, Institute for Protein Research, Osaka University, Suita, Japan.
Chun
S J
SJ
Niijima
A
A
Bizot-Espiard
J G
JG
Guardiola-Lemaitre
B
B
Hosokawa
M
M
Nagai
K
K
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D003847:Deoxyglucose / Q000008:administration & dosage / Q000494:pharmacology*; D005934:Glucagon / Q000097:blood / Q000378:metabolism; D006943:Hyperglycemia / Q000139:chemically induced / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008550:Melatonin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D001786:Blood Glucose; D007328:Insulin; D009281:Naphthalenes; C106874:N-(2-(1-naphthalenyl)ethyl)cyclobutanecarboxamide; D005934:Glucagon; D003847:Deoxyglucose; D008550:Melatonin